Protagonist Therapeutics Rallies on Rusfertide NDA Acceptance and Icotyde FDA Approval
Key Insights
Protagonist Therapeutics shares surged 64% over six months, driven by rusfertide's NDA acceptance with priority review for polycythemia vera (search) and a target action date of August 2026.
The FDA approved Icotyde (icotrokinra), the first oral targeted IL-23 receptor (search) peptide inhibitor, for moderate-to-severe plaque psoriasis (search), triggering a $50 million milestone payment to Protagonist.
Protagonist restructured its rusfertide partnership with Takeda (search), exiting U.S. profit-sharing in exchange for a $400 million upfront payment, up to $775 million in sales milestones, and tiered royalties of 14%-29%.
Shares of Protagonist Therapeutics have jumped 64% over the past six months, dramatically outpacing the industry's 4.5% growth, as investor confidence swells around the company's late-stage rare hematology candidate rusfertide and the newly approved immunology therapy Icotyde (icotrokinra).
The rally reflects a series of high-impact milestones: FDA acceptance of rusfertide's new drug application with priority review, the landmark approval of Icotyde as the first oral targeted peptide for moderate-to-severe plaque psoriasis (search), and a restructured partnership with Takeda (search) that significantly de-risks Protagonist's financial outlook.
Rusfertide Nears Commercialization with Priority Review
Rusfertide, a first-in-class subcutaneously administered hepcidin mimetic peptide, is being developed for polycythemia vera (search) (PV) in partnership with Takeda (search). The program advanced toward commercialization following positive phase III VERIFY data demonstrating superior hematocrit control, reduced phlebotomy requirements, and improved patient outcomes.
In March, the FDA accepted the new drug application for rusfertide with priority review, setting a target action date for August 2026. The priority review designation underscores the significant unmet need in polycythemia vera (search), a rare hematologic malignancy characterized by excessive red blood cell production.
Takeda (search) and Protagonist originally entered into a worldwide license and collaboration agreement for rusfertide in January 2024, under which Takeda became Protagonist's global co-development partner and gained the option to co-commercialize the drug in the United States with profits shared equally.
However, in a strategic move announced in April, Protagonist exited its U.S. profit-sharing agreement with Takeda (search). In exchange, Protagonist will receive a $400 million upfront payment — including a $200 million opt-out payment — a $75 million milestone payment upon FDA approval, up to $775 million in sales milestones, and tiered royalties of 14%-29% on global sales. This restructuring provides Protagonist with more predictable income and substantially reduces its commercial and financial risk.
Icotyde: First Oral Targeted Peptide Approved for Plaque Psoriasis (search)
Investor sentiment received an additional boost in March when the FDA approved Johnson & Johnson's icotrokinra for the treatment of adults and pediatric patients aged 12 years and above with moderate-to-severe plaque psoriasis (search) who are eligible for systemic therapy or phototherapy. Icotrokinra, an oral targeted peptide inhibitor of the IL-23 receptor (search), will be marketed as Icotyde in the United States.
Icotyde represents a significant milestone as the first and only FDA-approved targeted oral peptide for moderate-to-severe plaque psoriasis (search), potentially transforming the treatment landscape where currently available effective options are predominantly injectables, such as AbbVie (search)'s Skyrizi and Johnson & Johnson's own Tremfya.
The approval was based on robust data from four phase III studies — ICONIC-LEAD, ICONIC-TOTAL, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 — within the broader ICONIC development program evaluating Icotyde across plaque psoriasis (search) and psoriatic arthritis (search) indications.
Icotyde was co-developed by Protagonist and Johnson & Johnson, with Protagonist leading early-stage development while Johnson & Johnson holds exclusive global rights for late-stage development and commercialization across multiple indications under the companies' 2017 collaboration agreement. The FDA approval triggered a $50 million milestone payment to Protagonist, which remains eligible for up to $580 million in additional regulatory and sales milestones, along with tiered global royalties of 6%-10% on future net sales.
Beyond psoriasis, Icotyde is being evaluated across multiple indications, including active psoriatic arthritis (search), moderate-to-severe active ulcerative colitis (search), and Crohn's disease (search), reflecting its broader potential in inflammatory disease markets. The therapy is also under review in the European Union for the plaque psoriasis (search) indication, providing an additional near-term catalyst.
Wholly Owned Pipeline Advances
Protagonist continues to advance its wholly owned pipeline assets. PN-881, an oral IL-17 antagonist, is expected to complete phase I and enter phase II in 2026. The company is also progressing PN-477, a triple GLP/GIP/GCG agonist, toward phase I, while PN-458, a dual GLP/GIP agonist, and PN-8047, an oral hepcidin mimetic, remain in IND-enabling studies.
With rusfertide's PDUFA date set for August 2026, Icotyde's commercial launch underway, and a diversified pipeline advancing through development, Protagonist Therapeutics has positioned itself for a potentially transformative period ahead.